Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study tracks how well a targeted lung cancer drug works in everyday clinics

NCT ID NCT05703516

Recruiting now Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study follows 44 people in South Korea who have a specific type of lung cancer (NSCLC with MET exon 14 skipping mutation) and are taking the drug Capmatinib (Tabrecta). Researchers will monitor side effects and how well the drug shrinks tumors in real-world settings, not in a controlled lab environment. The goal is to confirm the drug's safety and effectiveness as it is used by doctors in routine practice.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Capmatinib (Tabrecta)
What this could lead to
If successful, this study will confirm that Capmatinib is safe and effective for treating a specific type of lung cancer in everyday clinical practice.
What could go wrong
This is an observational study, not a controlled trial, so results may be less definitive. Side effects are possible, and the small size (44 people) limits general conclusions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Adenocarcinoma of Lung lung neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CARCINOMA

Contacts and locations

Locations

  • Novartis Investigative Site

    RECRUITING

    Daegu, Dalseo gu, 42602, South Korea

  • Novartis Investigative Site

    RECRUITING

    Suwon, Gyeonggi-do, 16499, South Korea

  • Novartis Investigative Site

    RECRUITING

    Incheon, Korea, 405 760, South Korea

  • Novartis Investigative Site

    RECRUITING

    Seoul, Korea, 02447, South Korea

  • Novartis Investigative Site

    RECRUITING

    Seoul, Seoul, 06351, South Korea

  • Novartis Investigative Site

    RECRUITING

    Busan, 602-030, South Korea

  • Novartis Investigative Site

    RECRUITING

    Daejeon, 302-241, South Korea

  • Novartis Investigative Site

    RECRUITING

    Jeollanam, 519763, South Korea

  • Novartis Investigative Site

    RECRUITING

    Seoul, 05505, South Korea

  • Novartis Investigative Site

    RECRUITING

    Seoul, 06591, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.